Tg Therapeutics share price today
(NASDAQ: TGTX)

Name: Tg Therapeutics Share Price Today (NASDAQ: TGTX) - Tg Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Tg Therapeutics share price is $29.04 & ₹2,511.67 as on 24 Jan 2025, 2.30 'hrs' IST

$29.04

▲

-0.1

(-0.34%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Tg Therapeutics share price in Dollar and Rupees. Guide to invest in Tg Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Tg Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Tg Therapeutics share price movements

Today's Low: $28.74
Today's High: $29.42
$29.04
1.03%
Downside
Day's Volatility :2.31%
Upside
1.29%
52 Weeks Low: $12.84
52 Weeks High: $36.84
$29.04
55.79%
Downside
52 Weeks Volatility :65.15%
Upside
21.17%

Tg Therapeutics Returns

Period	Tg Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	24.74%	-5.5%	0.0%
6 Months	41.7%	-4.3%	0.0%
1 Year	82.35%	1.6%	0.0%
3 Years	97.43%	9.8%	-11.0%

Tg Therapeutics Key Statistics

in dollars & INR

Previous Close	$29.14
Open	$29.0
Today's High	$29.42
Today's Low	$28.74
Market Capitalization	$4.6B
Today's Volume	$2.1M
52 Week High	$36.84
52 Week Low	$12.84
Revenue TTM	$264.8M
EBITDA	$-408.0K
Earnings Per Share (EPS)	$-0.1
Profit Margin	-5.43%
Quarterly Earnings Growth YOY	-0.97%
Return On Equity TTM	-8.05%

How to invest in Tg Therapeutics Stock (TGTX) from India?

It is very easy for Indian residents to invest directly in Tg Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Tg Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Tg Therapeutics or TGTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Tg Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Tg Therapeutics shares which would translate to 0.030 fractional shares of Tg Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Tg Therapeutics, in just a few clicks!

Returns in Tg Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Tg Therapeutics investment value today

Current value as on today

₹1,85,782

Returns

₹85,782

(+85.78%)

Returns from Tg Therapeutics Stock

₹81,727 (+81.73%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Tg Therapeutics

-19%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Tg Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -19% less investors are searching Tg Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Tg Therapeutics

BlackRock Inc
14.10%
Vanguard Group Inc
9.88%
State Street Corp
5.84%
Pictet Asset Manangement SA
2.30%
Geode Capital Management, LLC
2.06%
Woodline Partners LP
1.65%

Analyst Recommendation on Tg Therapeutics

Buy

80%Buy

13%Hold

6%Sell

Based on 15 Wall street analysts offering stock ratings for Tg Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Tg Therapeutics

What analysts predicted

Upside of 41.18%

Target:

$41.00

Current:

$29.04

Insights on Tg Therapeutics

Price Movement
In the last 1 year, TGTX stock has moved up by 84.3%
Increasing Revenue
Revenue is up for the last 4 quarters, 43.97M → 83.87M (in $), with an average increase of 18.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 6.87M → 3.88M (in $), with an average decrease of 43.6% per quarter

Tg Therapeutics Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$152.0K	↑ 0.0%
Net Income	$-179.3M	↑ 3.38%
Net Profit Margin	-118.0K%	↓ 3858.56%

	FY20	Y/Y Change
Revenue	$152.0K	↑ 0.0%
Net Income	$-285.9M	↑ 59.4%
Net Profit Margin	-188.1K%	↓ 70086.18%

	FY21	Y/Y Change
Revenue	$6.7M	↑ 4300.66%
Net Income	$-355.6M	↑ 24.37%
Net Profit Margin	-5.3K%	↑ 182762.16%

	FY22	Y/Y Change
Revenue	$2.8M	↓ 58.36%
Net Income	$-203.8M	↓ 42.67%
Net Profit Margin	-7.3K%	↓ 2003.42%

	FY23	Y/Y Change
Revenue	$233.7M	↑ 8290.02%
Net Income	$12.7M	↓ 106.22%
Net Profit Margin	5.42%	↑ 7324.31%

	FY24	Y/Y Change
Revenue	$233.7M	↑ 0.0%
Net Income	$12.7M	↑ 0.0%
Net Profit Margin	5.42%	↑ 0.0%

	Q2 FY23	Q/Q Change
Revenue	$16.1M	↑ 106.0%
Net Income	$-47.6M	↑ 23.25%
Net Profit Margin	-296.19%	↑ 198.85%

	Q3 FY23	Q/Q Change
Revenue	$165.8M	↑ 931.57%
Net Income	$113.9M	↓ 339.3%
Net Profit Margin	68.71%	↑ 364.9%

	Q4 FY23	Q/Q Change
Revenue	$44.0M	↓ 73.48%
Net Income	$-14.4M	↓ 112.65%
Net Profit Margin	-32.79%	↓ 101.5%

	Q1 FY24	Q/Q Change
Revenue	$63.5M	↑ 44.35%
Net Income	$-10.7M	↓ 25.73%
Net Profit Margin	-16.87%	↑ 15.92%

	Q2 FY24	Q/Q Change
Revenue	$73.5M	↑ 15.74%
Net Income	$6.9M	↓ 164.25%
Net Profit Margin	9.36%	↑ 26.23%

	Q3 FY24	Q/Q Change
Revenue	$83.9M	↑ 14.17%
Net Income	$3.9M	↓ 43.6%
Net Profit Margin	4.63%	↓ 4.73%

	FY19	Y/Y Change
Profit	$-130.0K	↓ 303.12%

	FY20	Y/Y Change
Profit	$-222.0K	↑ 70.77%

	FY21	Y/Y Change
Profit	$5.9M	↓ 2757.21%

	FY22	Y/Y Change
Profit	$2.5M	↓ 57.28%

	FY23	Y/Y Change
Profit	$219.1M	↑ 8594.76%

	FY24	Y/Y Change
Profit	$219.5M	↑ 0.19%

	Q2 FY23	Q/Q Change
Profit	$14.2M	↑ 103.9%

	Q3 FY23	Q/Q Change
Profit	$162.3M	↑ 1045.99%

	Q4 FY23	Q/Q Change
Profit	$36.0M	↓ 77.8%

	Q1 FY24	Q/Q Change
Profit	$58.0M	↑ 60.86%

	Q2 FY24	Q/Q Change
Profit	$65.1M	↑ 12.32%

	Q3 FY24	Q/Q Change
Profit	$74.5M	↑ 14.52%

	FY19	Y/Y Change
Operating Cash Flow	$-132.8M	↑ 3.01%
Investing Cash Flow	$-718.0K	↓ 160.85%
Financing Cash Flow	$204.2M	↑ 79.7%

	FY20	Y/Y Change
Operating Cash Flow	$-214.5M	↑ 61.52%
Investing Cash Flow	$-24.5M	↑ 3313.65%
Financing Cash Flow	$679.8M	↑ 232.9%

	FY21	Y/Y Change
Operating Cash Flow	$-295.6M	↑ 37.82%
Investing Cash Flow	$-332.0K	↓ 98.65%
Financing Cash Flow	$41.4M	↓ 93.91%

	FY22	Y/Y Change
Operating Cash Flow	$-176.2M	↓ 40.41%
Investing Cash Flow	$-20.0M	↑ 5928.01%
Financing Cash Flow	$-391.0K	↓ 100.94%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-42.0M	↓ 29.88%
Investing Cash Flow	$30.5M	↓ 594.5%
Financing Cash Flow	$47.0M	↑ 86.41%

Tg Therapeutics Technicals Summary

Sell

Neutral

Buy

Tg Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Tg Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Tg Therapeutics Inc	-9.39%	41.7%	82.35%	97.43%	121.43%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Tg Therapeutics Inc	39.29	NA	0.0	0.16	-0.08	0.0	NA	1.34
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Tg Therapeutics Inc	Buy	$4.6B	121.43%	39.29	-5.43%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

About Tg Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Organization	Tg Therapeutics
Employees	319
CEO	Mr. Michael S. Weiss Esq.
Industry	Health Technology

Management People of Tg Therapeutics

Name	Title
Mr. Michael S. Weiss Esq.	Chairman, CEO & President
Mr. Sean A. Power CPA	CFO, Corporate Secretary & Treasurer
Ms. Jenna Bosco	Senior Vice President of Corporate Communications
Mr. Adam Waldman	Chief Commercialization Officer

Important FAQs about investing in Tg Therapeutics (TGTX) from India :

What is Tg Therapeutics share price today?

Tg Therapeutics share price today stands at $29.04, Open: $29.00 ; Previous Close: $29.14 ; High: $29.42 ; Low: $28.74 ; 52 Week High: $36.84 ; 52 Week Low: $12.84. The stock opens at $29.00, after a previous close of $29.14. The stock reached a daily high of $29.42 and a low of $28.74, with a 52-week high of $36.84 and a 52-week low of $12.84.

Can Indians buy Tg Therapeutics shares?

Yes, Indians can invest in the Tg Therapeutics (TGTX) from India.

With INDmoney, you can buy Tg Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Tg Therapeutics at zero transaction cost.

How can I buy Tg Therapeutics shares from India?

It is very easy to buy Tg Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Tg Therapeutics be purchased?

Yes, you can buy fractional shares of Tg Therapeutics with INDmoney app.

What are the documents required to start investing in Tg Therapeutics stocks?

To start investing in Tg Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.